Non-alcoholic steatohepatitis therapeutic - Viscient Biosciences
Latest Information Update: 01 Jun 2023
At a glance
- Originator Viscient Biosciences
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 02 May 2023 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)
- 02 May 2023 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis released by Viscient Biosciences
- 02 May 2023 Viscient Biosciences plans a clinical trial for Non-alcoholic steatohepatitis in 2024 (PO)